BridgeBio Pharma Inc (BBIO) — Financial Flexibility Index

Latest as of September 2025: -0.04x

BridgeBio Pharma Inc (BBIO) has a Financial Flexibility Index of -0.04x as of September 2025. Free cash flow of $-109.10 Million (operating CF $-109.57 Million minus capex $470.00K) represents 0% of total liabilities ($2.92 Billion). Also explore BridgeBio Pharma Inc annual equity growth to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.04x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-109.10 Million
Operating CF − Capex

Total Liabilities

$2.92 Billion
USD

Capital Expenditures

$470.00K
USD

BridgeBio Pharma Inc Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for BridgeBio Pharma Inc across 8 annual periods. Check BBIO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for BridgeBio Pharma Inc (2017–2024)

Year-by-year free cash flow to debt coverage for BridgeBio Pharma Inc. For the full company profile including market capitalisation, see how much is BridgeBio Pharma Inc worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.22x $-519.79 Million $-520.73 Million $2.38 Billion ▲ +21.5%
2023 -0.28x $-526.41 Million $-527.72 Million $1.89 Billion ▼ -26.0%
2022 -0.22x $-413.17 Million $-419.49 Million $1.87 Billion ▲ +7.6%
2021 -0.24x $-449.69 Million $-497.93 Million $1.88 Billion ▲ +63.6%
2020 -0.66x $-392.20 Million $-399.71 Million $595.70 Million ▲ +58.7%
2019 -1.60x $-248.45 Million $-253.59 Million $155.70 Million ▼ -663.0%
2018 -0.21x $-118.47 Million $-136.64 Million $566.44 Million ▲ +20.2%
2017 -0.26x $-40.02 Million $-40.49 Million $152.73 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities